Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron With Standard of Care Immunotherapy in Melanoma
NCT06508827Phase 2Withdrawn
- Sponsor
- Indiana University
- Start
- May 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of iron dextran in melanoma, sponsored by Indiana University. Primary endpoint: Erythroid progenitor cells detection in patient's blood. Planned start May 2025; status: withdrawn.
02
Drugs
iron dextran
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06508827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508827.